Company news
Gossamer Bio, Inc. news in 2024
Gossamer Bio, Inc.'s news releases, calls and decks from 2024, newest first.
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
August 25, 2024
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
August 11, 2024
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
May 13, 2024
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
May 5, 2024
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
May 2, 2024
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
March 11, 2024
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 4, 2024